|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0002499,
umls-concept:C0003232,
umls-concept:C0006826,
umls-concept:C0007559,
umls-concept:C0015967,
umls-concept:C0030705,
umls-concept:C0031955,
umls-concept:C0040808,
umls-concept:C0087111,
umls-concept:C1707455,
umls-concept:C1880496
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
1993-2-9
|
|
pubmed:abstractText |
A total of 170 febrile episodes in neutropenic patients with cancer were randomly assigned to be treated with piperacillin-amikacin or ceftazidime-amikacin. The overall response rates were similar in both groups (68 and 65%, respectively). Response rates for clinically or microbiologically documented episodes were 54.5% for piperacillin-amikacin and 58.8% for ceftazidime-amikacin. Response rates for gram-negative bacillary infections were 65 and 73%, respectively. There was also no difference for gram-positive infections (31 and 50%, respectively). The toxicities were also comparable and consisted of skin rashes, hypokalemia, and diarrhea. Vancomycin was added if the fever persisted 72 h after the beginning of therapy; it increased the response rates to 94% when used with piperacillin-amikacin and 92% when used with ceftazidime plus amikacin. Our results suggest that the combinations show similar global efficacies in the treatment of febrile episodes in cancer patients.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/1482151-1854169,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1482151-1911455,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1482151-2179420,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1482151-2403484,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1482151-2773965,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1482151-3041816,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1482151-3050517,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1482151-3066517,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1482151-3179173,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1482151-3325175,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1482151-3337513,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1482151-3521475,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1482151-3526155,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1482151-3526156,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1482151-3532942,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1482151-3890789,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1482151-3896712,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1482151-6211981,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1482151-6447455
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0066-4804
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
36
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2816-20
|
|
pubmed:dateRevised |
2010-9-7
|
|
pubmed:meshHeading |
pubmed-meshheading:1482151-Adult,
pubmed-meshheading:1482151-Aged,
pubmed-meshheading:1482151-Aged, 80 and over,
pubmed-meshheading:1482151-Amikacin,
pubmed-meshheading:1482151-Bacterial Infections,
pubmed-meshheading:1482151-Ceftazidime,
pubmed-meshheading:1482151-Drug Therapy, Combination,
pubmed-meshheading:1482151-Female,
pubmed-meshheading:1482151-Fever,
pubmed-meshheading:1482151-Humans,
pubmed-meshheading:1482151-Male,
pubmed-meshheading:1482151-Middle Aged,
pubmed-meshheading:1482151-Neoplasms,
pubmed-meshheading:1482151-Neutropenia,
pubmed-meshheading:1482151-Piperacillin,
pubmed-meshheading:1482151-Vancomycin
|
|
pubmed:year |
1992
|
|
pubmed:articleTitle |
Comparison of two antibiotic regimens (piperacillin plus amikacin versus ceftazidime plus amikacin) as empiric therapy for febrile neutropenic patients with cancer.
|
|
pubmed:affiliation |
Service of Medical Oncology, Hospital La Paz, Madrid, Spain.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial
|
